- |||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Trial completion, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Apr 6, 2018 P1, N=18, Completed, Active, not recruiting --> Terminated Active, not recruiting --> Completed
- |||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
New P1 trial, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 19, 2017 P1, N=18, Active, not recruiting,
- |||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Trial primary completion date, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 12, 2017 P1, N=18, Active, not recruiting, Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Dec 2015
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Aug 24, 2017 P1, N=27, Completed, Trial primary completion date: Jul 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- |||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Phase classification, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Jul 12, 2017 P, N=18, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016 Phase classification: P=N/A --> P | Phase classification: PN/A --> P1
- |||||||||| trebananib (AMG 386) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - May 4, 2017 P2, N=35, Completed, Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jan 2016 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Oct 28, 2016 P1, N=27, Active, not recruiting, Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016 N=60 --> 27
- |||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Enrollment closed, Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Jul 14, 2015 P=N/A, N=15, Active, not recruiting, N=15 --> 18 | Trial primary completion date: Dec 2015 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 | Recruiting --> Active, not recruiting
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - May 17, 2015 P3, N=659, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 | Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| trebananib (AMG 386) / Amgen
Trial completion, Combination therapy, Metastases: AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib (clinicaltrials.gov) - Feb 10, 2015 P2, N=152, Completed, N=200 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed
- |||||||||| nintedanib / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Dec 25, 2014 P2, N=36, Active, not recruiting, Active, not recruiting --> Completed Suspended --> Active, not recruiting | N=55 --> 36 | Trial primary completion date: Nov 2014 --> Nov 2015
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: High-dose Bevacizumab in Advanced Renal Carcinoma Patients (clinicaltrials.gov) - Dec 22, 2014 P2, N=119, Completed, Suspended --> Active, not recruiting | N=55 --> 36 | Trial primary completion date: Nov 2014 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2013
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Aug 7, 2014 P1, N=60, Active, not recruiting, Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment closed, Surgery: Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (clinicaltrials.gov) - Jan 7, 2014 P2, N=34, Active, not recruiting, Active, not recruiting --> Completed Completed --> Active, not recruiting
- |||||||||| Sutent (sunitinib) / Pfizer
New P2 trial: Sunitinib (clinicaltrials.gov) - Apr 3, 2013 P2, N=30, Recruiting,
- |||||||||| carboplatin / Generic mfg., amifostine / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer (clinicaltrials.gov) - Jun 12, 2012 P2, N=57, Completed, Initiation date: Jun 2012 --> Sep 2012 Active, not recruiting --> Completed
|